Analyst Insights Jan. 24th: CLDX, AONE, ZION, NCI

Celldex Therapeutics, Inc.(NASDAQ:CLDX): After Celldex updated its pipeline and several experts were very positive about the data presented by the company so far, Roth Capital expects the company ‘s stock to climb ahead of the ASCO conference in June. The firm reiterates a $6 target and Buy rating on the stock.

A123 Systems, Inc.(NASDAQ:AONE): Wunderlich notes that Fisker over the weekend cut its build plan for the Karma to 10,000 units from 12,000. The firm believes the move could save A123 Systems from having to raise additional capital for the remainder of 2012 since A123 money on every battery it makes for the Karma. Wunderlich keeps a Hold rating on A123 shares.

Zions Bancorp.(NASDAQ:ZION): Zions Bancorp weakness a buying opportunity, says JP Morgan. Zions Bancorporation Earnings: Swung to a Profit>>

Navigant Consulting Inc.(NYSE:NCI): Craig-Hallum said Navigant Consulting won a deal with Jordan’s Ministry of Energy for an LNG feasibility study. The analyst said Navigant remains a leader in the industry and reiterates its Buy rating.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.